Strategic Diagnostics Announces Progress in Advancing Clinical Biomarker Discovery
Successful Application of Technology in Cancer Biomarker Identification at M.D. Anderson Cancer Center
NEWARK, Del., October 25, 2007 - Strategic Diagnostics Inc. (Nasdaq: SDIX) today announced progress in collaborating with the Kleberg Center for Molecular
Markers at The University of Texas M. D. Anderson Cancer Center. The center
is currently testing SDI's Genomic Antibody Technology™ (GAT) platform in
oncology biomarker discovery research.
SDI's sequence-based GAT platform triggers the immune system of the host to
produce an antibody against a native protein. Through internal and third party
analysis, these antibodies have demonstrated superior performance in the
recognition and targeting of native protein targets in experimental models and
clinical samples as compared to reagents made with traditional methods.
Participating in a collaborative study, independent researchers at M. D. Anderson
have now used SDI's growing library of GAT antibodies to screen hundreds
of clinical cancer biopsy samples in a high throughput system to analyze the
differential presence of proteins in the tissue samples. The individual protein
signature of these samples created with SDI's reagents allows further research
into the clinical significance of the findings. The correlation of the data with the
corresponding disease state represented by the samples is focused on yielding
new tools to improve diagnostic, prognostic, and patient monitoring decisions.
Matthew H. Knight, SDI's President and Chief Executive Officer, stated, "As
demonstrated in the performance of our antibodies in the M. D. Anderson cancer
screens, the fundamental advantages of Genomic Antibody Technology™
clearly benefits the pace, scope, and precision of modern biomarker discovery.
We are encouraged by these results and are confident the next phase of the
offering's commercial expansion will further enable our scientists, collaborators
and customers in their efforts toward advancing the discovery and understanding
of significant protein patterns in human health."
Strategic Diagnostics offers custom service access to the Genomic Antibody
Technology™ platform in polyclonal and monoclonal products as well as a
rapidly expanding portfolio of Catalog Reagents targeting cancer markers.
These offerings complement SDI's breadth of traditional antibody development/
production services and clinical diagnostic products.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. is a leading provider of antibody technology to the Life Science
market place. Additionally the company provides biotechnology-based detection solutions
for a broad range of food, water, agricultural, and environmental applications. By applying its
core competencies of antibody and assay development, the Company produces unique,
sophisticated reagents, reagent systems, antibody design services and bio-detection solutions
to customer needs. Customers benefit from the enablement of their research into critical
health care challenges of disease understanding, therapeutic development and diagnostic
discovery. Industrial customers benefit with quantifiable "return on investment" by
reducing time, labor, and/or material costs. All this is accomplished while increasing
accuracy, reliability and actionability of essential test results. The Company is focused on
sustaining this competitive advantage by leveraging its expertise in antibody design,
immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue
its successful customer-focused research and development efforts. Recent innovations in
high throughput production of antibodies from genetic antigens will complement the
Company's established leadership in commercial and custom antibody production for the
Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the
Company for broader participation in proteomics research and discovery.
This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate",
"could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project", "plan" and similar expressions as they relate to
SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and
uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without
limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and
employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays
in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of
intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S.
Securities and Exchange Commission.
# # #